This year’s meeting of the American Society of Hematology (ASH) began yesterday morning in San Francisco.

Myeloma-related presentations were made during several sessions throughout the day.

The day started out with a session designed to better educate physicians about multiple myeloma and how to treat the disease.

Two sessions of oral presentations devoted solely to multiple myeloma ran simultaneously in the middle of the day. One of the sessions focused on the biology of the disease. The other one included presentations on new myeloma ther­a­pies for both newly diagnosed and re­lapsed and …

The 2014 annual meeting of the American Society of He­ma­tol­ogy (ASH) starts tomorrow, De­cem­ber 5, in San Francisco, and will con­tinue until next Tuesday.

The ASH annual meeting is one of sev­er­al large med­i­cal conferences where myeloma-related re­search findings are pre­sented each year.  However, from a mul­ti­ple myeloma perspective, the ASH meeting is generally the most im­por­tant of the meetings.

At this year’s meeting, for example, some 500 myeloma-presentations are scheduled to take place.  The pre­sen­ta­tions will summarize cur­rent re­search on a wide range of topics, in­clud­ing the biology of the dis­ease …

Yesterday was the second day of the American Society of Hematology’s (ASH) annual meeting, which is being held in New Orleans.

As on Saturday, myeloma-related presentations were once again made during several sessions throughout the day.

Experts who missed the education session on Saturday had the opportunity to attend the session again early Sunday morning.

One myeloma study was presented during the plenary session in the early afternoon. The six presentations in this session covered all blood cancers and are considered particularly important studies.

The myeloma study included in this session was …

This article is the second in The Beacon’s ‘preview’ series about mye­lo­ma re­search that will be pre­sented at the American Society of Hema­tol­o­gy (ASH) meet­ing in early December.

Abstracts for the ASH presentations are now available; these abstracts contain pre­lim­i­nary data, and updated data will be presented at the meet­ing.

The Beacon's ASH preview articles, which will be published over the next couple of weeks, will highlight the most interesting myeloma-related studies that will be presented at the meeting.

The first preview, which was published last …

Within the past nine months, two new agents have been approved for the treat­ment of re­lapsed mul­ti­ple myeloma.

In July 2012, a sec­ond gen­er­a­tion pro­te­a­some in­hib­i­tor, Kyprolis (car­filzomib), was approved for patients with re­lapsed/refractory dis­ease. In Feb­ru­ary of this year, Pomalyst (poma­lido­mide) was approved for use in similar patients.

These two agents, with dexamethasone (Decadron) or in com­bi­na­tion with other drugs, should fur­ther broaden the armamentarium for the treat­ment of myeloma as we con­tinue to strive to make myeloma a chronic dis­ease.

Rather than dwell on …

Yesterday was the sec­ond day of the 2012 American Society of He­ma­tol­ogy (ASH) annual meeting, which is being held in Atlanta.

The day's myeloma-related pre­sen­ta­tions began in the afternoon with three sessions of oral pre­sen­ta­tions.  Two of the sessions focused on re­­sults from clin­i­cal trials, most of which studied drugs that are still being devel­oped for the treat­ment of mul­ti­ple myeloma.  The third session, which focused on the biology of myeloma, ran simultaneously with one of the sessions about clin­i­cal trial re­­sults.

An up­date pub­lished yes­ter­day evening summarized the re­­sults for the …

During the upcoming annual meeting of the American Society of Hematology (ASH), which will be held December 8 through 11 in Atlanta, results will be presented from clin­i­cal trials involving a number of poten­tial new drugs under devel­op­ment for the treat­ment of multiple myeloma.

In particular, results for newer, lesser known agents that are in the early stages of clin­i­cal devel­op­ment will take center stage. These agents in­clude ARRY-520 (filanesib), BHQ880, circularly permuted TRAIL, daratumumab, dinaciclib, lorvotuzumab mertansine, oprozomib, and tabalumab.

According to the recently …